CSBio CSBio

X
[{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALK Gains Paediatric Approval for Its Ragweed Slit-Tablet in the USA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"ALK"},{"orgOrder":0,"company":"ALK","sponsor":"Grandpharma","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"ALK and Grandpharma Team Up to Market the First Adrenaline Autoinjector in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"ALK"},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Waiver in China Opens Door to 2022 Registration Filing for ALK's Dust Mite Allergy Tablet","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ALK"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            ALK

            Contact Supplier
            • Development Update

            Details:

            A waiver from Chinese authorities allows ALK to file for regulatory approval in China without finalising its paused local registration trial for ACARIZAX® (HDM SLIT), tablet for treatment of HDM allergic rhinitis for 12-65 year-olds and HDM allergic asthma in 18-65 year-olds.

            Lead Product(s): House Dust Mite Allergen Extract

            Therapeutic Area: Immunology Product Name: Acarizax

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            ALK

            Contact Supplier
            • Deals

            Details:

            Jext® is expected to be the first AAI to market in China. Prior to registration in mainland China, Grandpharma plans to start selling Jext® in southern China under a special licence linked to the existing registration of Jext® in Hong Kong.

            Lead Product(s): Epinephrine Bitartrate

            Therapeutic Area: Immunology Product Name: Jext

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Grandpharma

            Deal Size: $14.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            ALK

            Contact Supplier
            • Development Update

            Details:

            ALK has gained approval from the US Food and Drug Administration, to expand the use of ALK’s ragweed sublingual allergy immunotherapy (SLIT) tablet RAGWITEK® (RAGWIZAX® in Europe) to include paediatric patients, down to the age of 5, with ragweed-induced allergic rhinitis.

            Lead Product(s): Short Ragweed Pollen Allergen Extract

            Therapeutic Area: Immunology Product Name: Ragwitek

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY